MDT-AP-2993
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 15.96
- os_event
- false
- age_years
- 13
- sex
- M
- new_clusters
- C5
- umap1_2d
- 6.366104728
- umap2_2d
- 4.803352443
- umap1_3d
- 3.087609703
- umap2_3d
- -0.821946026
- umap3_3d
- -1.987143625
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- PANCREAS_BETA_CELLS+0.270
- SPERMATOGENESIS+0.150
- PI3K_AKT_MTOR_SIGNALING+0.050
- HEME_METABOLISM+0.010
- KRAS_SIGNALING_UP-0.020
- KRAS_SIGNALING_DN-0.030
- APICAL_SURFACE-0.050
- BILE_ACID_METABOLISM-0.090
- UNFOLDED_PROTEIN_RESPONSE-0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- ANGIOGENESIS-0.440
- E2F_TARGETS-0.410
- MYC_TARGETS_V2-0.390
- G2M_CHECKPOINT-0.370
- APOPTOSIS-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
- MYOGENESIS-0.330
- MYC_TARGETS_V1-0.300
- INFLAMMATORY_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2989 | Med | Medulloblastoma | 0.859 |
| 2 | SRR8943010 | — | — | 0.857 |
| 3 | R141 | — | — | 0.856 |
| 4 | MDT-AP-0153 | Med | Medulloblastoma | 0.855 |
| 5 | BS_FEPRNEXX | Embryonal tumors | — | 0.850 |
| 6 | SRR1443713 | GTEX | — | 0.838 |
| 7 | MNG36 | — | — | 0.837 |
| 8 | MDT-AP-2991 | Med | Medulloblastoma | 0.835 |
| 9 | SRR975556 | — | — | 0.832 |
| 10 | 5231481f-3568-46e3-aa4d-cbd9c4e95383 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |